Evidence map›Paper›PMID 35876504›Full record

ArticleFuture oncology (London, England)2022

Plain language summary of NRG1 fusions in cancer: current knowledge and treatment with afatinib and other drugs.

Stephen V Liu

Open access · hybridAbstract readCommentPatient Education Handout
PubMed Publisher
In one paragraph

Article in Future oncology (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Stephen V LiuGeorgetown University Medical Center, Washington, DC, USA.
Georgetown University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

WHAT IS THIS STUDY ABOUT?: This plain language summary reports the findings of a recent review of WHAT ARE FUSIONS?: A gene fusion occurs when two genes join to create a new gene. This rearrangement of DNA can change the processes within normal cells and lead to cancer. One of these gene fusions involves the WHAT TREATMENTS ARE AVAILABLE FOR PEOPLE WITH FUSION-POSITIVE CANCER?: One drug that has been studied in people with

Indexed as

Lung NeoplasmsAfatinibBiologyHumansLanguageNeuregulin-1Oncogene Proteins, FusionAfatinibNeuregulin-1NRG1 protein, humanOncogene Proteins, Fusionafatiniblay summaryNeuregulin-1NRG1 fusionsplain language summary

Identifiers

PMID35876504
OpenAlexW4287377385

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.